Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford's Colorectal Cancer Stratified Medicine Network

Colorectal cancer (CRC) remains the second most common cause of cancer death, and patients with stage 3/4 cancers at diagnosis only have a 10% survival rate at 5 years.

CRC presents an opportunity for precision medicine as it is common cancer, has known and established driver molecular pathways, and pre-treatment molecular stratification is achievable.

ACRCelerate brings together a European-wide consortium of researchers at the forefront of CRC research. Researchers Prof Simon Leedham and Prof Tim Maughan lead the work from Oxford, collaborating with researchers across the UK, Italy and Spain.

The overall aim of the consortium is to generate robust and reproducible preclinical data to de-risk future clinical trials based on patient stratification. This will be achieved through:

  • developing preclinical models that recapitulate the molecular subtypes of CRC and characterising their signalling pathways
  • using DNA and RNA sequencing to subtype the models, identify and test new therapeutics
  • integrating data in a bioinformatic analysis pipeline

This research is currently funded by CRUK.

Existing collaborations across the network. The hubs of the network are shown with their existing internal and external collaborationsExisting collaborations across the network. The hubs of the network are shown with their existing internal and external collaborations

This international network prevents proprietary duplication of work, enhances collaboration and training and facilitates result validation.This international network prevents proprietary duplication of work, enhances collaboration and training and facilitates result validation.

Colorectal Cancer News

Blood tests provide no additional information to FIT alone when prioritising patients for colorectal cancer referral

Faecal immunochemical testing (FIT) alone leads to the identification of the same number of patients with colorectal cancer as more complicated approaches that combine the FIT result with the results of commonly used blood tests.

FOCUS4: a flagship trial in colorectal cancer

Professor Tim Maughan outlines the flagship work of the FOCUS4 trials, whose results were presented this weekend at the European Society of Medical Oncology (ESMO) annual meeting

Eoghan Mulholland awarded colorectal cancer fellowship

As part of UK Pride month, we are spotlighting the work of cancer researcher and University LGBTQ+ Representative Dr Eoghan Mulholland